BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia

被引:0
作者
Chong, Stephen Jun Fei [1 ,2 ,5 ]
Lu, Junyan [3 ]
Valentin, Rebecca [1 ,4 ]
Lehmberg, Timothy Z. [1 ]
Eu, Jie Qing [5 ]
Wang, Jing [1 ]
Zhu, Fen [1 ]
Kong, Li Ren [5 ]
Fernandes, Stacey M. [1 ]
Zhang, Jeremy [1 ]
Herbaux, Charles [1 ]
Goh, Boon Cher [5 ]
Brown, Jennifer R. [1 ]
Niemann, Carsten U. [4 ]
Huber, Wolfgang [6 ]
Zenz, Thorsten [7 ,8 ]
Davids, Matthew S. [1 ]
机构
[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Natl Univ Singapore NUS, NUS Ctr Canc Res N2CR, Dept Physiol, Singapore, Singapore
[3] Heidelberg Univ, Med Fac Heidelberg, Heidelberg, Germany
[4] Dept Hematol, Rigshosp, Copenhagen, Denmark
[5] NUS, Canc Sci Inst Singapore, N2CR, Singapore, Singapore
[6] European Mol Biol Lab, Heidelberg, Germany
[7] Univ Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland
[8] Univ Hosp Zurich, Zurich, Switzerland
关键词
NF-KAPPA-B; DNA-DAMAGE; APOPTOSIS; MUTATIONS; PHOSPHORYLATION; VENETOCLAX; EXPRESSION; RESISTANCE; CELLS; NOXA;
D O I
10.1186/s12943-025-02260-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundEstablished genetic biomarkers in chronic lymphocytic leukemia (CLL) have been useful in predicting response to chemoimmunotherapy but are less predictive of response to targeted therapies. With several such targeted therapies now approved for CLL, identifying novel, non-genetic predictive biomarkers of response may help to select the optimal therapy for individual patients.MethodsWe coupled data from a functional precision medicine technique called BH3-profiling, which assesses cellular cytochrome c loss levels as indicators for survival dependence on anti-apoptotic proteins, with multi-omics data consisting of targeted and whole-exome sequencing, genome-wide DNA methylation profiles, RNA-sequencing, protein and functional analyses, to identify biomarkers for treatment response in CLL patients.ResultsWe initially studied 73 CLL patients from a discovery cohort. We found that greater dependence on the anti-apoptotic BCL-2 protein was associated with prognostically favorable genetic biomarkers. Furthermore, BCL-2 dependence was strongly associated with gene expression patterns and signaling pathways that suggest a more targeted drug-sensitive milieu and was predictive of drug responses. We subsequently demonstrated that these associations were causal in cell lines and additional CLL patient samples. To validate the findings from our discovery cohort and in vitro studies, we utilized primary CLL cells from 54 additional patients treated on a prospective, phase-2 clinical trial of the BTK inhibitor ibrutinib given in combination with chemoimmunotherapy (fludarabine, cyclophosphamide, rituximab) and confirmed in this independent dataset that higher BCL-2 dependence predicted favorable clinical response, independent of the genetic background of the CLL cells.ConclusionWe comprehensively defined BCL-2 dependence as a potential functional and predictive biomarker of treatment response in CLL, underscoring the importance of characterizing apoptotic signaling in CLL to stratify patients beyond genetic markers and identifying novel combinations to exploit BCL-2 dependence therapeutically. Our approach has the potential to help optimize targeted therapy combinations for CLL patients.
引用
收藏
页数:19
相关论文
共 57 条
  • [1] Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways
    Abruzzo, Lynne V.
    Herling, Carmen D.
    Calin, George A.
    Oakes, Christopher
    Barron, Lynn L.
    Banks, Haley E.
    Katju, Vikram
    Keating, Michael J.
    Coombes, Kevin R.
    [J]. HAEMATOLOGICA, 2018, 103 (12) : 2069 - 2078
  • [2] Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
    Ahn, Inhye E.
    Brander, Danielle M.
    Ren, Yue
    Zhou, Yinglu
    Tyekucheva, Svitlana
    Walker, Heather A.
    Black, Robert
    Montegaard, Josie
    Alencar, Alvaro
    Shune, Leyla
    Omaira, Mohammad
    Jacobson, Caron A.
    Armand, Philippe
    Ng, Samuel Y.
    Crombie, Jennifer
    Fisher, David C.
    LaCasce, Ann S.
    Arnason, Jon
    Hochberg, Ephraim P.
    Takvorian, Ronald W.
    Abramson, Jeremy S.
    Brown, Jennifer R.
    Davids, Matthew S.
    [J]. BLOOD ADVANCES, 2024, 8 (04) : 832 - 841
  • [3] The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
    Anderson, Mary Ann
    Deng, Jing
    Seymour, John F.
    Tam, Constantine
    Kim, Su Young
    Fein, Joshua
    Yu, Lijian
    Brown, Jennifer R.
    Westerman, David
    Si, Eric G.
    Majewski, Ian J.
    Segal, David
    Enschede, Sari L. Heitner
    Huang, David C. S.
    Davids, Matthew S.
    Letai, Anthony
    Roberts, Andrew W.
    [J]. BLOOD, 2016, 127 (25) : 3215 - 3224
  • [4] The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD
    Bernard, D
    Monte, D
    Vandenbunder, B
    Abbadie, C
    [J]. ONCOGENE, 2002, 21 (28) : 4392 - 4402
  • [5] Targeting Oxidative Phosphorylation to Increase the Efficacy of Radio- and Immune-Combination Therapy
    Boreel, Daan F.
    Span, Paul N.
    Heskamp, Sandra
    Adema, Gosse J.
    Bussink, Johan
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (11) : 2970 - 2978
  • [6] Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment
    Bosc, Claudie
    Selak, Mary A.
    Sarry, Jean-Emmanuel
    [J]. CELL METABOLISM, 2017, 26 (05) : 705 - 707
  • [7] Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven E.
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie
    Sharman, Jeff P.
    Wierda, William
    Zhao, Weiqiang
    Heerema, Nyla A.
    Luan, Ying
    Liu, Emily A.
    Dean, James P.
    O'Brien, Susan
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (15) : 3918 - 3927
  • [8] Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
    Catz, SD
    Johnson, JL
    [J]. ONCOGENE, 2001, 20 (50) : 7342 - 7351
  • [9] Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2
    Chen, Z. X.
    Pervaiz, S.
    [J]. CELL DEATH AND DIFFERENTIATION, 2010, 17 (03) : 408 - 420
  • [10] NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells
    Chiou, Jing-Ting
    Huang, Nan-Chieh
    Huang, Chia-Hui
    Wang, Liang-Jun
    Lee, Yuan-Chin
    Shi, Yi-Jun
    Chang, Long-Sen
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (11) : 7356 - 7375